These human antibodies target the protein, protogenin, to reduce growth of medulloblastomas. Medulloblastoma is one of the most prevalent forms of pediatric brain cancer, accounting for up to 20% of cases. Currently, medulloblastoma is treated with a combination of surgical removal, radiation therapy, and chemotherapy. With these treatment options, recurrence rates amongst children are 30% and recurrence is typically fatal. Immunotherapy is a promising form of treatment that manipulates the immune system to fight cancer. Although it has been successfully applied to other forms including bladder and lung cancer, immunotherapy has been previously unsuccessful in treating brain cancers such as medulloblastoma.
Cell. 2024 Jul 5;187(17):4733–4750.e26.